Dr. Cho on the Updated Efficacy of Repotrectinib in TKI-Naïve ROS1+ NSCLC


Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.

Byoung Chul Cho, MD, PhD, a professor at the Yonsei Cancer Center and Severance Hospital, discusses the updated efficacy reported with repotrectinib (TPX-0005) in TKI-naïve patients with ROS1-positive non–small cell lung cancer (NSCLC).

The updated efficacy data from the phase 2 TRIDENT-1 study, as well as the pooled data from the phase 1/2 portion of the study, were presented during the 2020 World Conference on Lung Cancer, according to Cho.

Clinical activity was observed in patients who were TKI naïve with ROS1-positive NSCLC in the phase 1/2 portion of the trial. These patients had received at least 2 post-baseline scans, notes Cho. These patients achieved a high and promising response rate, says Cho. Moreover, patients from the phase 2 portion of the trial experienced a high confirmed objective response rate, Cho concludes.

Related Videos
Experts on lung cancer
Experts on lung cancer
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Joachim G. J. V. Aerts, MD, PhD
Alessandro Di Federico, MD
Expert on SCLC
Dazhi Liu, PharmD, MS, BCOP
Stephen V. Liu, MD
Sanam Loghavi, MD
Experts on lung cancer
Related Content